Self-administration of omalizumab: why not? A literature review and expert opinion.
|
| Abstract |
Introduction: Omalizumab is used to treat severe uncontrolled allergic asthma and chronic spontaneous urticaria (CSU), and is approved for self-administration in prefilled syringes. It is thus important to understand the advantages, critical issues, and indications for home administration.Areas covered: The present review summarizes the available evidence on home administration of omalizumab in asthma and CSU to illustrate the advantages derived from self-administration of patients in this setting.Expert opinion: The available data suggest that patients can safely administer biologics at home with suitable training, and that home administration is time saving and cost-effective. The majority of patients with severe asthma or CSU treated with omalizumab are likely to be suitable candidates for self-administration, which can be proposed to anyone that the clinician deems suitable. In addition to clinicians, pharmacists can also play a key role in managing patients who are prescribed home administration. A practical flow chart is proposed on selection of patients and their management during home administration. Self-administration of biologics can be considered as a valid alternative to traditional injections in a clinical setting, and the evidence has shown that no major issues need to be overcome in terms of safety or efficacy.
|
|---|---|
| Authors | Francesco Menzella, Emanuele Ferrari, Silvia Mariel Ferrucci, Enrico Lombardi, Silvio Alfano, Ornella Bonavita, Paolo Morini, Andrea Rizzi, Andrea Matucci |
| Journal | Expert opinion on biological therapy (Expert Opin Biol Ther) Vol. 21 Issue 4 Pg. 499-507 (04 2021) ISSN: 1744-7682 [Electronic] England |
| PMID | 33504237 (Publication Type: Journal Article, Research Support, Non-U.S. Gov't, Review) |
| Chemical References |
|
| Topics |
|
Join CureHunter, for free Research Interface BASIC access!
Realize the full power of the drug-disease research graph!